Loading...
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
PURPOSE: The association between initial molecular response and longer-term outcomes with nilotinib was examined. PATIENTS AND METHODS: Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline...
Na minha lista:
| Udgivet i: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Clinical Oncology
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979159/ https://ncbi.nlm.nih.gov/pubmed/23109697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.5217 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|